Global Neurotech Devices Market Size & Trends Report Segmented by Product (Neurostimulators, Neuroprosthetics, Neurorehabilitation), Application (Chronic Pain Management, Epilepsy, Cognitive Disorders), End-user Analysis, and Regional Forecast to 2030

Overview

Neurotechnology (Neurotech) devices refer to medical and technological tools designed to monitor, assess, and interact with the nervous system, particularly the brain and spinal cord. These devices are used in the diagnosis and treatment of individuals with neurological conditions. They are also used to enhance cognitive and motor functions in both clinical and non-clinical settings. Neurotech devices are making a meaningful impact in healthcare by helping doctors and researchers better understand and treat conditions that affect the brain and nervous system.

To learn more about this report, download the PDF brochure

Technological advancements drive growth in neurotech devices market

The neurotech devices market is witnessing steady growth, largely driven by ongoing technological advancements in the field of neurology. These innovations have transformed the way neurological conditions are diagnosed, monitored, and treated, resulting in better patient outcomes and expanded their applications in the neurological healthcare sector beyond clinical environments. The integration of advanced technologies, such as artificial intelligence, machine learning, and real-time data processing, has greatly improved the functionality and accuracy of devices like brain-computer interfaces (BCIs), neurostimulation systems, and neuroimaging tools.

One of the most impactful outcomes of these advancements is the development of minimally invasive brain-computer interfaces (BCIs), which have created new possibilities for people living with paralysis or other neurological conditions. These devices allow such individuals to control external devices like computers or robotic limbs with their brain signals. Similarly, next-generation closed-loop neurostimulation devices offer personalized treatment by adjusting stimulation levels based on the patient’s real-time neural activity. This personalized approach is helping improve the quality of life for patients dealing with epilepsy, Parkinson’s disease, chronic pain, and other challenging conditions. Some of the technological advancements are listed below-

• In February 2025, Medtronic received FDA approval for its BrainSense Adaptive deep brain stimulation (aDBS) and Electrode Identifier. This technology, combined with its Percept DBS neurostimulators, has enabled real-time, personalized therapy that automatically adjusts based on a patient’s brain activity to improve Parkinson’s symptom control without manual intervention
• In January 2025, Medtronic received CE mark approval for its BrainSense Adaptive closed-loop DBS technology in Europe, which can automatically adjust stimulation, based on real-time brain activity signals and thereby enhance personalized DBS therapy for people with Parkinson's
• In April 2024, Medtronic received FDA approval for its Inceptiv closed-loop SCS, which senses biological signals from the spinal cord and automatically adjusts stimulation in real time to treat chronic pain. It also offers full-body MRI access and is the smallest fully implantable SCS to date
• In August 2022, Abbott received FDA approval for its Proclaim Plus Spinal Cord Stimulation (SCS) system, allowing tailored pain relief across multiple body regions using its FlexBurst360 therapy, which also supports remote adjustments through its NeuroSphere Virtual Clinic and offers a 10-year battery life without recharging

The miniaturization of neurotech devices and the development of AI-powered wearables have also enabled the use of neurotech devices in non-clinical settings, including at-home cognitive training, mental health monitoring, and sleep tracking. These advanced devices have features like wireless connectivity and companion apps, which allow patients and clinicians to remotely monitor brain activity and respond proactively. These user-friendly, portable devices are expanding access to neurological healthcare and encouraging early intervention.

To learn more about this report, download the PDF brochure

Emergence of closed-loop neurostimulation systems

A closed-loop stimulation system is an advanced neurostimulation technology designed to deliver adaptive and patient-specific impulses. Unlike open-loop systems that provide continuous, pre-programmed electrical impulses irrespective of the physiological feedback, closed-loop systems include real-time monitoring and adjustments of stimulation parameters based on real-time neural activity. These systems are incorporated with advanced sensors and algorithms, thereby providing precise personalized therapies. As a result, they are being increasingly adopted in the treatment of neurological and neuropsychiatric conditions like Parkinson’s disease, epilepsy, chronic pain, and depression. The ability of closed-loop systems to provide personalized therapies is not only improving the treatment effectiveness but also aligning with the growing demand for user-friendly, home-based and personalized neurology healthcare solutions. Along with their technological capabilities, these systems are being proven effective in improving clinical outcomes.

Competitive Landscape Analysis

The global neurotech devices market is shaped by several leading players actively advancing the field through innovation and strategic growth. Key companies include Medtronic plc; Abbott Laboratories; Boston Scientific Corporation; NeuroPace, Inc.; LivaNova PLC; Nevro Corp.; BioSerenity SAS; Tivic Health Systems, Inc.; Synchron, Inc.; and Nihon Kohden Corporation, among others. These companies are focusing on advancements in brain-computer interfaces, closed-loop stimulation systems, and wearable neurostimulation technologies, while also pursuing partnerships, clinical trials, and regional market expansion strategies to strengthen their global footprint.

Report Scope

Global Neurotech Devices Market Segmentation

This report by Medi-Tech Insights provides the size of the global neurotech devices market at the regional- and country-level from 2023 to 2030. The report further segments the market based on product, application, and end-user.

Market Size & Forecast (2023-2030), By Product, USD Million

• Neurostimulation Devices
• Neuroprosthetics
• Neurorehabilitation Devices
• Neurosensing Devices
• Others

Market Size & Forecast (2023-2030), By Application, USD Million

• Chronic Pain Management
• Epilepsy
• Cognitive Disorders
• Depression
• Others

Market Size & Forecast (2023-2030), By End-user, USD Million

• Hospitals
• Outpatient Surgical Centers
• Home-care Facilities
• Others

Market Size & Forecast (2023-2030), By Region, USD Million

• North America
  • US
  • Canada
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Rest of Asia Pacific
• Latin America
• Middle East & Africa

Key Strategic Questions Addressed

• What is the market size & forecast of the neurotech devices market?
• What are historical, present, and forecasted market shares and growth rates of various segments and sub-segments of the neurotech devices market?
• What are the key trends defining the market?
• What are the major factors impacting the market?
• What are the opportunities prevailing in the market?
• Which region has the highest share in the global market? Which region is expected to witness the highest growth rate in the next 5 years?
• Who are the major players operating in the market?
• What are the key strategies adopted by players?